Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Astellas

EU flag

Second Remicade biosimilar given green light in Europe

Samsung Bioepis’ Flixabi provides another lower-cost treatment option

National Institute for Health and Care Excellence NICE logo

NICE gives green light to Sanofi’s Jevtana for prostate cancer

Undisclosed discount for NHS encourages U-turn to back the chemotherapy drug

- PMLiVE

J&J gets European OK for myeloma therapy Darzalex

First-in-class immunotherapy achieved ‘significant increase’ in overall survival

UK Life Sciences Strategy - one year on

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

eHealth set to benefit from EC’s ‘single digital market’

Says will help European industry, researchers and public authorities

Sanofi reception

Sanofi hints at sweetened Medivation deal – or hostile bid

CEO Oliver Brandicourt claims “overwhelming support” for deal from shareholders

Sanofi reception

Medivation unimpressed with Sanofi’s offer

CEO says the offer “substantially undervalues” the oncology specialist

- PMLiVE

Astellas appoints ethics and compliance and US legal leaders

Mark Wanda, Nahrin Marino and Matt Silversten take up new roles

Sanofi reception

Sanofi makes $9.3bn unsolicited bid for Medivation

Hopes to boost oncology business with fast-growing prostate cancer drug Xtandi

Eli Lilly HQ

Lilly’s psoriasis drug Taltz cleared in Europe

Clinicians suggest the IL-17 inhibitor has “best-in-class data”

- PMLiVE

Astellas names Bob Chib to development leadership role

He takes up corporate strategy and planning position

- PMLiVE

Gilead bags EU approval for next-generation HIV drug

Descovy expected to replace Truvada as the firm’s lead antiviral blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links